Insider Selling: Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Sells 50,000 Shares of Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE) CEO Burke Thomas Barrett sold 50,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. The trade was a 44.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Pulse Biosciences Stock Performance

NASDAQ:PLSE traded up $0.19 during trading hours on Friday, hitting $17.98. The company’s stock had a trading volume of 166,773 shares, compared to its average volume of 200,640. The stock has a fifty day simple moving average of $17.90 and a 200-day simple moving average of $16.57. Pulse Biosciences, Inc. has a twelve month low of $6.59 and a twelve month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the company earned ($0.19) EPS.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Thursday, December 12th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quest Partners LLC bought a new stake in Pulse Biosciences during the 2nd quarter worth $91,000. Creative Planning boosted its stake in shares of Pulse Biosciences by 113.9% during the third quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after purchasing an additional 11,667 shares in the last quarter. Franklin Resources Inc. bought a new stake in shares of Pulse Biosciences during the third quarter worth about $378,000. Rhumbline Advisers increased its stake in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after buying an additional 1,608 shares during the period. Finally, Barclays PLC raised its holdings in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after buying an additional 23,738 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.